Trials / Completed
CompletedNCT00004895
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Northwestern University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.
Detailed description
OBJECTIVES: * Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer. * Characterize the dose and tolerability of octreotide in this patient population. OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5. Patients who respond well to study may continue octreotide for palliative effects. PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
Conditions
- Colorectal Cancer
- Constipation, Impaction, and Bowel Obstruction
- Extrahepatic Bile Duct Cancer
- Gastric Cancer
- Gastrointestinal Stromal Tumor
- Nausea and Vomiting
- Ovarian Cancer
- Pancreatic Cancer
- Peritoneal Cavity Cancer
- Small Intestine Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | octreotide acetate |
Timeline
- Start date
- 1999-10-01
- Primary completion
- 2002-10-01
- Completion
- 2002-10-01
- First posted
- 2003-05-09
- Last updated
- 2012-06-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00004895. Inclusion in this directory is not an endorsement.